Enliven Therapeutics (NASDAQ:ELVN) Insider Joseph Lyssikatos Sells 1,500 Shares

Key Points

• Insider Trading: Joseph Lyssikatos, an insider at Enliven Therapeutics, sold 1,500 shares at an average price of $20.03, resulting in a total transaction value of $30,045.
• Stock Performance: Enliven Therapeutics' stock is currently down 3.3%, trading at $18.57, with an average target price from analysts set at $41.20.
• Analyst Ratings: Multiple analysts have upgraded their price targets for Enliven Therapeutics, with HC Wainwright raising theirs to $48.00 and Robert W. Baird to $52.00, indicating positive sentiment in the market.

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) insider Joseph Lyssikatos sold 1,500 shares of the company's stock in a transaction that occurred on Tuesday, September 23rd. The stock was sold at an average price of $20.03, for a total value of $30,045.00. Following the transaction, the insider directly owned 931,688 shares in the company, valued at $18,661,710.64. The trade was a 0.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Enliven Therapeutics Stock Down 3.3%

ELVN traded down $0.63 during trading on Thursday, hitting $18.57. 277,472 shares of the company's stock were exchanged, compared to its average volume of 598,101. The business's 50 day moving average is $19.86 and its two-hundred day moving average is $19.62. Enliven Therapeutics, Inc. has a fifty-two week low of $13.30 and a fifty-two week high of $30.03. The stock has a market cap of $1.10 billion, a P/E ratio of -9.29 and a beta of 0.89.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.53) by $0.04. On average, sell-side analysts forecast that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Analyst Upgrades and Downgrades

ELVN has been the topic of several analyst reports. HC Wainwright lifted their target price on Enliven Therapeutics from $40.00 to $48.00 and gave the company a "buy" rating in a research report on Wednesday, July 2nd. Robert W. Baird lifted their price objective on shares of Enliven Therapeutics from $40.00 to $52.00 and gave the stock an "outperform" rating in a report on Monday, June 16th. Finally, The Goldman Sachs Group began coverage on shares of Enliven Therapeutics in a research note on Monday, June 16th. They issued a "buy" rating and a $37.00 target price for the company. Five investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Enliven Therapeutics has an average rating of "Buy" and an average price target of $41.20.

Hedge Funds Weigh In On Enliven Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Ameriprise Financial Inc. purchased a new position in Enliven Therapeutics in the fourth quarter valued at about $789,000. Goldman Sachs Group Inc. lifted its position in shares of Enliven Therapeutics by 61.3% during the first quarter. Goldman Sachs Group Inc. now owns 211,752 shares of the company's stock worth $4,167,000 after acquiring an additional 80,506 shares in the last quarter. Millennium Management LLC boosted its stake in Enliven Therapeutics by 108.6% in the 4th quarter. Millennium Management LLC now owns 50,804 shares of the company's stock worth $1,143,000 after purchasing an additional 26,449 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Enliven Therapeutics by 67.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 43,714 shares of the company's stock valued at $984,000 after acquiring an additional 17,546 shares in the last quarter. Finally, Rhumbline Advisers boosted its holdings in Enliven Therapeutics by 4.9% in the 1st quarter. Rhumbline Advisers now owns 52,502 shares of the company's stock valued at $1,033,000 after purchasing an additional 2,466 shares during the period. Institutional investors own 95.08% of the company's stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.